Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELEASE: Fimaporfin-induced PCI in inoperable cholangiocarcinoma
NCT04099888Phase 2Terminated
- Sponsor
- PCI Biotech
- Start
- May 2019
- Primary completion
- Apr 2022
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 14
01
Overview
A Phase 2 trial of fimaporfin in cholangiocarcinoma (CCA), sponsored by PCI Biotech. Started May 2019; status: terminated.
02
Drugs
fimaporfin
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT04099888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04099888.